EMAIL THIS PAGE TO A FRIEND

Journal of immunotherapy (Hagerstown, Md. : 1997)

Ex vivo generation of interstitial and Langerhans cell-like dendritic cell subset-based vaccines for hematological malignancies.


PMID 24810638

Abstract

Autologous, patient-specific, monocyte-derived dendritic cell (MoDC) vaccines have been successfully applied in the clinical studies so far. However, the routine application of this strategy has been hampered by the difficulties in generating sufficient numbers of DC and the poor DC vaccine quality because of pathology or prior treatment received by the patients. The immunotherapeutic potential of other subsets of DC has not been thoroughly investigated because of their rarity in tissues and difficulties associated with their ex vivo generation. The high expansion and differentiation potential of CD34 hematopoietic progenitor cells (HPC), isolated from umbilical cord blood (UCB), into different DC subsets make them an attractive alternative DC source for cancer immunotherapy. Therefore, the aim of this study was to generate a large number of different DC subsets from CD34 HPC and evaluate their functionality in comparison with MoDC. Our culture protocol generated a clinically relevant number of mature CD1a myeloid DC and CD207 Langerhans cells (LC)-like DC subsets from CD34 HPC with >95% purity. Both DC subsets exhibited a cytokine profile that favors cytotoxic T-cell responses. Furthermore, UCB-DC and UCB-LC demonstrated superior induction of proliferation of both allogeneic as well as viral antigen-specific CD8 T cells, both in vitro and in vivo. Additional studies revealed that UCC-DC and UCB-LC can efficiently expand minor histocompatibility antigen (MiHA) HA-1-specific cytotoxic T cells in the peripheral blood of leukemia patients and prime MiHA HA-1-specific and HA-2-specific cytotoxic T cells in vitro. These preclinical findings support the pharmaceutical development of the described culture protocol for clinical evaluation.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA004252
Anti-CD4 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA004472
Anti-CD4 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1405577
Anti-CD8A antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA037756
Anti-CD8A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4700059
Monoclonal Anti-CD4 , (N-terminal) antibody produced in mouse, clone MEM-241, purified immunoglobulin, buffered aqueous solution
C1805 Monoclonal Anti-CD4 antibody produced in mouse, clone Q4120, purified immunoglobulin, buffered aqueous solution
SAB4700054 Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-16, purified immunoglobulin, buffered aqueous solution
SAB4700065
Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-115, purified immunoglobulin, buffered aqueous solution
SAB4700733 Monoclonal Anti-CD4 antibody produced in mouse, clone OX-35, purified immunoglobulin, buffered aqueous solution
SAB4100489
Monoclonal Anti-CD4 antibody produced in mouse, clone CD4 -A409, culture supernatant
AMAB90754
Monoclonal Anti-CD4 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0395, purified immunoglobulin, buffered aqueous glycerol solution
C7423
Monoclonal Anti-CD8 antibody produced in mouse, clone UCHT-4, purified immunoglobulin, buffered aqueous solution
SAB4700084 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-31, purified immunoglobulin, buffered aqueous solution
SAB4700089 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-87, purified immunoglobulin, buffered aqueous solution
SAB1402142
Monoclonal Anti-CD8A antibody produced in mouse, clone 4B9, purified immunoglobulin, buffered aqueous solution